(Q36299086)

English

Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab -- a translational project in the neoadjuvant GeparQuinto trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab -- a translational project in the neoadjuvant GeparQuinto trial (English)

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

1 reference

based on heuristic

inferred from title

Peter A. Fasching

10

object named as

P A Fasching

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

2

object named as

S Loibl

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

20

object named as

M Untch

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

author name string

I Witzel

1

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

G von Minckwitz

3

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

H Eidtmann

4

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

T Fehm

5

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

F Khandan

6

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

S Schmatloch

7

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

M Hauschild

8

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

J Bischoff

9

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

C Mau

11

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

C Schem

12

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

B Rack

13

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

I Meinhold-Heerlein

14

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

C Liedtke

15

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

T Karn

16

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

J Huober

17

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

C Zu Eulenburg

18

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Y Issa-Nummer

19

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

V Müller

21

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

language of work or name

0 references

publication date

14 August 2012

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

British Journal of Cancer

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

107

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

6

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

956-960

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3464767

30 September 2017

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3464767

30 September 2017

HER2 shedding and serum HER2 extracellular domain: biology and clinical utility in breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3464767

30 September 2017

Lapatinib for breast cancer: a review of the current literature

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3464767

30 September 2017

Lapatinib, a dual HER1/HER2 tyrosine kinase inhibitor, augments basal cleavage of HER2 extracellular domain (ECD) to inhibit HER2-driven cancer cell growth

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3464767

30 September 2017

Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3464767

30 September 2017

Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3464767

30 September 2017

Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3464767

30 September 2017

Her-2/neu-triggered intracellular tyrosine kinase activation: in vivo relevance of ligand-independent activation mechanisms and impact upon the efficacy of trastuzumab-based treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3464767

30 September 2017

Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3464767

30 September 2017

Dual inhibition of HER2 in breast cancer treatment.

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.353

21 January 2018

Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.353

21 January 2018

Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.353

21 January 2018

Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study.

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.353

21 January 2018

Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.353

21 January 2018

Human epidermal growth factor receptor 2 (HER2) extracellular domain levels are associated with progression-free survival in patients with HER2-positive metastatic breast cancer receiving lapatinib monotherapy.

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.353

21 January 2018

Reporting recommendations for tumor marker prognostic studies (REMARK).

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.353

21 January 2018

Prognostic and predictive impact of the HER-2/ neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.353

21 January 2018

Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.353

21 January 2018

Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial.

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.353

21 January 2018

Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.353

21 January 2018

Monitoring of serum Her-2/neu predicts histopathological response to neoadjuvant trastuzumab-based therapy for breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3464767

22 September 2018

NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22892393

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/22892393

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New guidelines for reporting of tumor marker studies in breast cancer research and treatment: REMARK

1 reference

https://pubmed.ncbi.nlm.nih.gov/22892393

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/22892393

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/22892393

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Is circulating HER-2 more than just a tumor marker?

1 reference

https://pubmed.ncbi.nlm.nih.gov/22892393

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/BJC.2012.353

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36299086&oldid=2198601248"